Eli Lilly’s once-daily oral pill orforglipron outperformed oral semaglutide in reducing blood sugar and body weight over 52 weeks in adults with type 2 diabetes, according to results from the ACHIEVE-3 Phase 3 trial. The multinational, randomized study tested both drugs head-to-head in patients whose diabetes was not adequately controlled on metformin alone. The findings, now published in The Lancet, raise a direct challenge to Novo Nordisk’s oral Ozempic and could reshape first-line prescribing for millions of people managing type 2 diabetes with pills rather than injections.
Why orforglipron’s edge over oral semaglutide matters right now
The GLP-1 receptor agonist class has been dominated by injectable drugs like semaglutide and tirzepatide, but patient demand for effective oral alternatives has surged. Oral semaglutide, marketed as Rybelsus, was the first GLP-1 pill to reach the market, yet its absorption profile requires strict fasting rules and dose-escalation schedules that limit how much active drug patients actually receive. Orforglipron is a small molecule, not a peptide, which means it does not face the same gastrointestinal absorption barriers. That structural difference is central to understanding the ACHIEVE-3 outcome.
The working hypothesis is straightforward: because orforglipron can be absorbed more efficiently without the fasting constraints that limit oral semaglutide’s bioavailability, clinicians can push effective dosing higher with fewer titration-related dropouts. If both drugs were tested at truly matched systemic exposure levels, the gap between them might narrow or disappear. ACHIEVE-3 was designed as a non-inferiority trial, meaning it set out to prove orforglipron was at least as good as oral semaglutide. That it showed superiority on both glycemic control and weight loss suggests orforglipron’s pharmacological profile allowed it to deliver more drug effect in practice, even if the two molecules target the same receptor.
For patients, the practical difference is significant. A pill that works better without requiring a 30-minute fast before eating or drinking could mean fewer missed doses and better long-term adherence. For clinicians, it introduces a credible oral alternative that may delay or eliminate the need to escalate to injectable therapy. Health systems and payers, meanwhile, may view a more effective oral GLP-1 as an opportunity to reduce complications and associated costs if long-term outcomes track with the short-term metabolic improvements seen in ACHIEVE-3.
What ACHIEVE-3 and related trials actually measured
ACHIEVE-3 enrolled adults with type 2 diabetes inadequately controlled on metformin and randomized them to receive either once-daily oral orforglipron or oral semaglutide. The trial ran across multiple countries and centers over 52 weeks, with primary endpoints focused on change in HbA1c, the standard measure of average blood sugar over roughly three months. Weight change served as a key secondary outcome. The trial’s registry entry confirms the open-label design, treatment arms, and planned sample size, though full numerical results for HbA1c reduction and mean weight change require the complete Lancet dataset rather than the registry abstract alone.
The open-label design is a limitation worth examining. Patients and investigators knew which drug they were taking, which can influence subjective reporting and adherence behavior. Still, HbA1c and body weight are objective, laboratory-confirmed endpoints that are harder to bias through expectation effects alone. Where expectations might matter more is in how aggressively clinicians support dose escalation or how patients tolerate early gastrointestinal side effects, both of which can influence how much drug exposure is achieved over the course of the study.
Orforglipron’s evidence base extends beyond this single head-to-head comparison. A separate Phase 3 trial, ACHIEVE-5, tested orforglipron as an add-on to titrated insulin glargine in patients with type 2 diabetes and found consistent efficacy and tolerability signals. That result matters because it shows the drug performs across different treatment contexts, not just in the specific metformin-background population of ACHIEVE-3. In combination with basal insulin, maintaining glycemic benefits without unacceptable hypoglycemia or intolerable side effects is particularly challenging, so the ACHIEVE-5 data help build confidence that orforglipron’s effects are robust.
Separately, the OASIS 4 trial established weight-loss benchmarks for a higher 25 mg dose of oral semaglutide in adults with overweight or obesity, providing context for how aggressively Novo Nordisk has been pushing its own oral formulation to compete on weight outcomes. While OASIS 4 did not directly compare against orforglipron, it underscores that both companies see oral GLP-1 therapies as central to future obesity and diabetes strategies, and that dose optimization is still a moving target.
The competitive picture is sharpening. Novo Nordisk has been developing higher-dose oral semaglutide formulations precisely because the current approved doses leave room for improvement. Eli Lilly’s orforglipron, by contrast, appears to achieve strong results through a fundamentally different absorption mechanism rather than simply increasing the dose of an existing peptide. If payers ultimately view orforglipron as delivering more “GLP-1 effect” per pill with fewer administration constraints, formulary negotiations could favor Lilly’s drug, especially in markets where injection hesitancy has slowed uptake of injectable GLP-1s.
Gaps in the evidence and what patients should watch next
Several questions remain open. The full comparative safety tables and discontinuation rates between the two drugs are not available from the trial registry or PubMed abstract alone. Gastrointestinal side effects, particularly nausea and vomiting during dose escalation, are the most common reason patients stop GLP-1 drugs. Whether orforglipron’s small-molecule structure translates into fewer of these events, or simply different timing, will matter enormously for real-world adoption. The complete Lancet publication should contain these details, but independent analysis of the safety data will take time.
Another gap involves durability. ACHIEVE-3 followed patients for 52 weeks, which is an important milestone, but type 2 diabetes is a lifelong condition. It remains unclear whether the HbA1c and weight advantages seen with orforglipron over oral semaglutide will persist, narrow, or widen over several years. Long-term extension studies and post-marketing surveillance will be needed to determine whether patients maintain weight loss, avoid plateauing, and experience any late-emerging safety concerns such as rare gastrointestinal or pancreatic events.
Cardiovascular outcomes are a further unknown. Injectable semaglutide has demonstrated cardiovascular benefit in high-risk populations, which has been a major driver of its use in diabetes and obesity. Orforglipron, as a newer agent, does not yet have completed dedicated cardiovascular outcomes data. Regulators may require such trials, and clinicians will want to see whether the metabolic advantages observed in ACHIEVE-3 translate into fewer heart attacks, strokes, or cardiovascular deaths over time.
For patients and prescribers deciding between therapies, practical considerations will also shape choices. Insurance coverage and list prices are not yet fully defined for orforglipron, and co-pay differences could outweigh modest clinical advantages for many people. Some patients may prefer to stay with a familiar brand like semaglutide, especially if they have already navigated dose titration successfully. Others may prioritize the simpler administration and potentially greater efficacy of orforglipron, particularly if they have struggled to reach glycemic or weight targets on existing oral options.
What is clear from the available data is that oral GLP-1 therapy is entering a new phase. ACHIEVE-3 shows that a thoughtfully designed small-molecule agonist can not only match but surpass the first generation of peptide-based oral GLP-1 drugs under real-world dosing conditions. As safety, durability, and cardiovascular findings accumulate, the balance of evidence will determine whether orforglipron becomes the preferred oral GLP-1 for type 2 diabetes-or whether higher-dose semaglutide formulations and future competitors can close the gap. For now, patients should view the emerging options as an expanding toolkit and work with their clinicians to find the oral regimen that best fits their medical needs, lifestyle, and tolerance for side effects.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
